Brazil opens the cannabis export door: what it actually takes to reach the EU

Brazil has, for the first time, written down how cannabis active pharmaceutical ingredients (IFAs) and finished medicinal-cannabis products made on its own soil may be exported. RDC 1.023/2026, dated 11 May 2026, sets the rules on labelling, classification and dispensation, and — the new part — the export activity itself, and aligns the controlled-substances portaria (Portaria SVS/MS nº 344/1998) with the framework ANVISA approved in January, chiefly RDC 1.015/2026, which replaced the seven-year-old RDC 327/2019. The product must carry, as its active ingredient, only CBD or an extract from a CBD-dominant chemotype of Cannabis sativa L.; cultivation for export is capped at 0.3% THC; and volumes have to be backed by contracts or letters of intent to buy, sell or distribute. Customs procedures follow ANVISA's existing import-export resolutions (RDC 988/2025 and RDC 81/2008).

Read in isolation that sounds like a market opening. Read against the ground it is closer to a statement of intent. Brazil barely produces medicinal cannabis at scale: the domestic cultivation rules (RDC 1.013/2026) only take effect in August 2026, the country still imports most of the extracts and IFAs its patients consume, and a large share of supply runs through patient associations that operate without formal ANVISA authorisation. Around 850,000 Brazilians use medicinal cannabis, yet the structured, GMP-grade production base an export programme assumes is still being built. The honest framing — and ANVISA's own — is industrial policy: the rule exists so the supply chain has somewhere to grow into, not because export volume is waiting at the port.

For anyone reading this from the supply side, the binding constraint is not in Brasília. It is the EU's. Medicinal cannabis sold in the bloc is a medicine, governed by Directive 2001/83/EC, and that means EU-GMP certification is the gate: no product enters a member-state pharmacy chain without it, and certification is granted on inspection by national authorities — Germany's BfArM, Portugal's Infarmed, Denmark's DKMA among them, all of which already inspect overseas producers. There is no single European cannabis market to sell into. Import and narcotics licensing sit with each member state, separately, so a Brazilian exporter is not entering 'the EU' but a specific country, under that country's controlled-drugs regime, one at a time.

In practice that country is almost always Germany first. By most estimates Germany takes close to half of all EU medical-cannabis imports by value, and its market is now worth well over a billion euros a year and growing — the rest of the bloc is real but fragmented and far smaller. So the practical route for a Brazilian IFA or extract is narrower than the headline suggests: secure EU-GMP certification for the relevant line, line up a licensed importer in the target country who holds the narcotics permits, and only then talk volume. The order matters; the certification and the importer come before the first container, not after.

None of this makes the change small. A permanent export pathway is something Brazil did not have a month ago, and the producers who get EU-GMP and a German importer in place early will be the ones holding the contracts when domestic cultivation finally scales. But it is a door, not a corridor — the work between the two is certification, member-state licensing and a buyer who can actually receive the goods. If your route runs Brazil → EU in cannabis IFAs or derivatives, the scan maps which of those gates sits on your critical path, what EU-GMP and narcotics licensing your target market will demand, and where the realistic demand actually is.